文献速递主动脉外科

抗血小板治疗对广泛修复后A型主动脉夹层患者降胸主动脉转归及长期预后的影响

The impact of antiplatelet therapy on the descending thoracic aorta fate and long-term prognosis of extensive repaired type A aortic dissection.
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

该研究纳入2010年1月至2019年12月1147例广泛修复的A型主动脉夹层患者,分为非抗血小板组(754例)和抗血小板组(393例)。结果显示两组5年总体生存率、降胸主动脉假腔血栓形成、主动脉再扩张、再干预或破裂及主要出血事件均无显著差异。作者认为抗血小板治疗可按指征用于广泛修复的A型主动脉夹层患者。

要点

  • 抗血小板治疗未影响广泛修复A型主动脉夹层患者的远期降胸主动脉假腔血栓形成。
  • 抗血小板治疗未影响主动脉再扩张、再干预或破裂及主要出血事件。
  • 抗血小板治疗未影响总体生存,作者认为可按指征使用。

核心结论

  • 抗血小板治疗未影响广泛修复A型主动脉夹层患者的远期降胸主动脉假腔血栓形成、再扩张、再干预或破裂、主要出血事件或总体生存。
  • 因此,抗血小板治疗可按指征用于广泛修复的A型主动脉夹层患者。

研究设计与样本

  • 研究纳入2010年1月至2019年12月1147例符合条件的广泛修复A型主动脉夹层患者,分为非抗血小板组(n=754)和抗血小板组(n=393)。
  • 主要终点为总体生存和降胸主动脉重构(包括假腔血栓形成和主动脉再扩张),次要终点为降胸主动脉再干预或破裂及主要出血事件。

主要发现

  • 非抗血小板组与抗血小板组的5年总体生存率分别为95.6%和94.3%(P=0.53)。
  • 在支架覆盖段,非抗血小板组与抗血小板组的1年假腔完全血栓形成率分别为92.1%和92.4%(P=0.27)。
  • 在支架未覆盖段,非抗血小板组与抗血小板组的5年假腔完全血栓形成率分别为47.1%和56.5%(P=0.12)。
  • 抗血小板治疗不是肺动脉分叉水平(β±SE=-0.128±0.203,P=0.53)、膈肌水平(β±SE=0.143±0.152,P=0.35)或腹腔干水平(β±SE=0.049±0.136,P=0.72)主动脉再扩张的独立预测因素。
  • 以死亡为竞争风险,非抗血小板组与抗血小板组的5年降胸主动脉再干预或破裂累积发生率分别为4.6%和4.0%(sHR=0.85,95%CI 0.49~1.19;P=0.58),5年主要出血事件累积发生率分别为2.1%和2.3%(sHR=0.82,95%CI 0.56~2.67;P=0.62)。

临床怎么用

  • 作者认为,抗血小板治疗可按指征用于广泛修复的A型主动脉夹层患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the impact of antiplatelet therapy on the long-term descending thoracic aorta (DTA) fate and prognosis of extensive repaired type A aortic dissection (TAAD). METHODS: 1147 eligible TAAD patients from January 2010 to December 2019 were stratified into non-antiplatelet (n = 754) and antiplatelet groups (n = 393). The primary end points were overall survival, and DTA remodelling, including false lumen (FL) thrombosis and aortic redilation. The secondary end points were DTA reintervention or rupture and major bleeding events (MBEs). RESULTS: The 5-year overall survival rates were 95.6% and 94.3% in the non-antiplatelet and antiplatelet groups (P = 0.53), respectively. In the stent covering segment, the 1-year FL complete thrombosis rates were 92.1% and 92.4% in the non-antiplatelet and antiplatelet groups (P = 0.27), respectively, while in the stent uncovering segment, the 5-year FL complete thrombosis rates were 47.1% and 56.5% in the non-antiplatelet and antiplatelet groups (P = 0.12), respectively. Antiplatelet therapy was not an independent predictor of aortic redilation at the pulmonary artery bifurcation (β±SE = -0.128 ± 0.203, P = 0.53), diaphragm (β±SE = 0.143 ± 0.152, P = 0.35) or coeliac artery (β±SE = 0.049 ± 0.136, P = 0.72) levels. With death as a competing risk, the cumulative incidences of DTA reintervention or rupture at 5 years were 4.6% and 4.0% in the non-antiplatelet and antiplatelet groups (sHR = 0.85, 95% CI, 0.49∼1.19; P = 0.58), respectively, and the 5-year cumulative incidences of MBEs were 2.1% and 2.3% in the non-antiplatelet and antiplatelet groups (sHR = 0.82, 95% CI, 0.56∼2.67; P = 0.62), respectively. CONCLUSIONS: Antiplatelet therapy did not impact long-term DTA FL thrombosis, redilation, reintervention or rupture, MBEs or overall survival on extensive repaired TAAD. Thus, antiplatelet therapy can be administered as indicated on extensive repaired TAAD.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Zhang B, Dun Y, Liu Y, et al. The impact of antiplatelet therapy on the descending thoracic aorta fate and long-term prognosis of extensive repaired type A aortic dissection. Eur J Cardiothorac Surg. 2023. PMID: 37166479. doi:10.1093/ejcts/ezad186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。